Abstracts tagged "axial spondyloarthritis"

Abstract Number: 1864 • 2018 ACR/ARHP Annual Meeting
Ixekizumab Significantly Improves Signs, Symptoms, and Spinal Inflammation of Active Ankylosing Spondylitis/Radiographic Axial Spondyloarthritis: 16-Week Results of a Phase 3 Randomized, Active and Placebo-Controlled Trial
Désirée van der Heijde¹, James Cheng-Chung Wei², Maxime Dougados³, Philip J. Mease⁴, Atul A. Deodhar⁵, Walter P. Maksymowych⁶, Filip van Den Bosch⁷, Joachim Sieper⁸, Tetsuya Tomita⁹, Robert B.M. Landewé¹⁰, Lotus Mallbris¹¹, Fangyi Zhao¹¹, David Adams¹¹, Beth Pangallo¹¹ and Hilde Carlier¹¹, ¹Leiden University Medical Centre, Leiden, Netherlands, ²Allergy/Immunology/Rheumatology, Chung Shan Med Univ Hospital, Taichung, Taiwan, ³Rheumatology Department, Cochin Hospital, AP-HP, Paris Descartes University, Paris, France, Paris, France, ⁴Swedish Medical Center and University of Washington, Seattle, WA, ⁵Oregon Health & Science U, Portland, OR, ⁶University of Alberta, Edmonton, AB, Canada, ⁷Ghent University Hospital, Ghent, Belgium, Ghent, Belgium, ⁸Charité University Hospital, Berlin, Germany, ⁹Department of Orthopedics, Osaka University Graduate School of Medicine, Suita Osaka, Japan, ¹⁰Amsterdam Rheumatology & Clinical Immunology Center and Zuyderland Medical Center, Amsterdam; Heerlen, Netherlands, ¹¹Eli Lilly and Company, Indianapolis, IN
Background/Purpose: COAST-V (NCT02696785) is the first phase 3 study of ixekizumab (IXE), a high-affinity anti-IL-17A monoclonal antibody, in patients (pts) with active radiographic axial SpA…
Abstract Number: 666 • 2018 ACR/ARHP Annual Meeting
Inflammation on MRI of the Sacroiliac Joints Is Highly Associated with Structural Damage in Axial Spondyloarthritis Patients in Clinical Practice: Data from the ASAS and DESIR Cohorts
Alexandre Sepriano¹, Sofia Ramiro^1,2, Robert B.M. Landewé^3,4, Maxime Dougados⁵, Désirée van der Heijde⁶ and Martin Rudwaleit⁷, ¹Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ²Zuyderland Medical Center, Heerlen & Leiden University Medical Center, Leiden, Netherlands, ³Zuyderland Medical Center, Heerlen, Netherlands, ⁴Amsterdam Rheumatology & Immunology Center, Amsterdam, the Netherlands, Amsterdam, Netherlands, ⁵Department of Rheumatology, Paris Descartes University and Cochin Hospital, Paris, France, ⁶Leiden University Medical Centre, Leiden, Netherlands, ⁷Internal Medicine and Rheumatology, Klinikum Bielefeld Rosenhöhe, Bielefeld, Germany
Background/Purpose: The effect of MRI-detected inflammation on the development of radiographic damage at the sacroiliac joints (SIJ) level in patients (pts) with axial SpA (axSpA)…
Abstract Number: 1867 • 2018 ACR/ARHP Annual Meeting
Drug Retention and Response Rates of TNFi Treatment in 21,470 Patients with Axial Spondyloarthritis Treated in Clinical Practice– Pooled Data from the Eurospa Research Network Collaboration
Cecilie Heegaard Brahe¹, Lykke Midtbøll Ørnbjerg¹, Johan Askling², Adrian Ciurea³, Eirik K Kristianslund⁴, Fatos Onen⁵, Dan Nordström⁶, Maria José Santos⁷, Catalin Codreanu⁸, Ziga Rotar⁹, Björn Gudbjornsson¹⁰, Daniela Di Giuseppe², Michael J. Nissen¹¹, Tore Kvien⁴, Merih Birlik⁵, Nina Trokovic⁶, Anabela Barcelos⁷, Ruxandra Ionescu⁸, Matija Tomšič⁹, Arni Jon Geirsson¹⁰, Anne Gitte Loft¹, Herman F Mann¹², Tamara Rusman¹³, Juan J. Gomez-Reino¹⁴, Gareth T. Jones¹⁵, Florenzo Iannone¹⁶, Karel Pavelka¹², Irene van der Horst-Bruinsma¹⁷, Lise Hyldstrup¹, Niels Steen Krogh¹⁸, Merete Lund Hetland¹ and Mikkel Østergaard¹, ¹DANBIO, EuroSpA Research Collaboration Network, Coordinating Centre, Copenhagen, Denmark, ²ARTIS, EuroSpA Research Collaboration Network, Stockholm, Sweden, ³SCQM, EuroSpA Research Collaboration Network, Zurich, Switzerland, ⁴NOR-DMARD, EuroSpA Research Collaboration Network, Oslo, Norway, ⁵TURKBIO, EuroSpA Research Collaboration Network, Izmir, Turkey, ⁶ROB-FIN, EuroSpA Research Collaboration Network, Helsinki, Finland, ⁷Reuma.pt, EuroSpA Research Collaboration Network, Lisbon, Portugal, ⁸RRBR, EuroSpA Research Collaboration Network, Bucharest, Romania, ⁹biorx.si, EuroSpA Research Collaboration Network, Ljubljana, Slovenia, ¹⁰ICEBIO, EuroSpA Research Collaboration Network, Reykjavik, Iceland, ¹¹SCQM, EuroSpA Research Collaboration Network, Geneva, Switzerland, ¹²ATTRA, EuroSpA Research Collaboration Network, Prague, Czech Republic, ¹³ARC, EuroSpA Research Collaboration Network, Haarlem, Netherlands, ¹⁴BIOBADASER, EuroSpA Research Collaboration Network, Santiago, Spain, ¹⁵BSRBR-AS, EuroSpA Research Collaboration Network, Aberdeen, United Kingdom, ¹⁶GISEA, EuroSpA Research Collaboration Network, Bari, Italy, ¹⁷ARC, EuroSpA Research Collaboration Network, Harleem, Netherlands, ¹⁸Zitelab, EuroSpA Research Collaboration Network, Copenhagen, Denmark
Drug retention and response rates of TNFi treatment in 21,470 patients with axial spondyloarthritis treated in clinical practice– pooled data from the EuroSpA Research Network…
Abstract Number: 675 • 2018 ACR/ARHP Annual Meeting
Quantitative Ultrasound of the Calcaneus Has a Role to Play in Detecting Low Bone Mineral Density in Axial Spondyloarthropathy Patients
Gillian Fitzgerald^1,2, Tochukwu Anachebe³, Ronan Mullan⁴, David Kane⁵, Kevin McCarroll⁶ and Finbar O' Shea², ¹School of Medicine, Trinity College Dublin, Dublin 2, Ireland, ²Rheumatology, St. James's Hospital, Dublin 8, Ireland, ³Department of Rheumatology, St. James's Hospital, Dublin 8, Ireland, ⁴Department of Rheumatology,, Tallaght Hospital, Dublin, Ireland, ⁵Department of Rheumatology, Tallaght Hospital, Dublin 24, Ireland, ⁶Department of Medicine for the Elderly, St. James's Hospital, Dublin 8, Ireland
Background/Purpose: Axial spondyloarthropathy (axSpA) patients have an increased risk of developing osteoporosis compared to matched controls. Dual energy x-ray absorptiometry (DXA) is the technique of…
Abstract Number: 1868 • 2018 ACR/ARHP Annual Meeting
Efficacy and Safety Outcomes in Patients with Non-Radiographic Axial Spondyloarthritis Treated with Certolizumab Pegol: Results from the First 52-Week Randomized Placebo-Controlled Study (NCT02552212)
Atul A. Deodhar¹, Lianne S. Gensler², Jonathan Kay³, Walter P. Maksymowych⁴, Nigil Haroon⁵, Robert B.M. Landewé⁶, Martin Rudwaleit⁷, Stephen Hall⁸, Lars Bauer⁹, Bengt Hoepken⁹, Natasha de Peyrecave¹⁰, Brian Kilgallen¹¹ and Désirée van der Heijde¹², ¹Oregon Health and Science University, Portland, OR, ²University of California San Francisco, San Francisco, CA, ³Division of Rheumatology, University of Massachusetts Medical School and UMass Memorial Medical Center, Worcester, MA, ⁴Department of Medicine, University of Alberta, Edmonton, AB, Canada, ⁵University Health Network, University of Toronto, Toronto, ON, Canada, ⁶Amsterdam Rheumatology & Clinical Immunology Center and Zuyderland Medical Center, Amsterdam; Heerlen, Netherlands, ⁷Department of Internal Medicine and Rheumatology, Klinikum Bielefeld, Bielefeld, Germany, ⁸Cabrini Medical Centre, Cabrini Private Hospital, Malvern, Australia, ⁹UCB Pharma, Monheim, Germany, ¹⁰UCB Pharma, Brussels, Belgium, ¹¹UCB Pharma, Raleigh, NC, ¹²Department of Rheumatology, Leiden University Medical Center, Leiden, Netherlands
Background/Purpose: In the USA, certolizumab pegol (CZP) is approved for treatment of adults with active ankylosing spondylitis (AS) and not for non-radiographic axial spondyloarthritis (nr-axSpA).…
Abstract Number: 678 • 2018 ACR/ARHP Annual Meeting
Ultrasonographic Evaluation of Achilles Tendon in Early Axial Spondyloarthropathy: Is There Any Difference between Ankylosing Spondylitis and Non-Radiographic Axial Spondyloarthropathy?
Shahla Vahidfar¹, Ismihan Sunar², Sebnem Ataman³, Gürkan Yılmaz⁴, Javid M. AZARABADI⁵ and Ayşe Bölükbaşı¹, ¹Physical Medicine and Rehabilitation, Ankara University Faculty of Medicine, Ankara, Turkey, ²Department of Physical Medicine and Rehabilitation, Division of Rheumatology,, Ankara University, Faculty of Medicine, Ankara, Turkey, ³Department of Physical Medicine and Rehabilitation, Division of Rheumatology, Ankara University Faculty of Medicine, Ankara, Turkey, ⁴Physical Medicine and Rehabilitation, Rheumatology Division, Ankara University Faculty of Medicine, Ankara, Turkey, ⁵ORTHOPEDICS AND TRAUMATOLOGY, Başkent University Faculty of Medicine, Ankara, Turkey
Background/Purpose: Along with emergence of the term of ‘non-radiographic axial SpA’ (nr-AxSpA), studies comparing AS and nr-AxSpA in terms of genetic, epidemiologic, and clinical issues…
Abstract Number: 2062 • 2018 ACR/ARHP Annual Meeting
Omentin-1: Potential Biomarker of Cardiovascular Risk in Axial Spondyloarthritis? a Serological and Genetic Study
Fernanda Genre¹, Javier Rueda-Gotor¹, Sara Remuzgo-Martínez¹, Verónica Pulito-Cueto¹, Alfonso Corrales¹, Verónica Mijares¹, Leticia Lera-Gómez¹, Virginia Portilla¹, Rosa Expósito², Cristina Mata², Iván Ferraz-Amaro³, M. Vanesa Hernandez-Hernandez⁴, Santos Castañeda⁵, Esther Vicente⁵, Cristina Fernández-Carballido⁶, María Paz Martínez-Vidal⁷, David Castro-Corredor⁸, Joaquín Anino-Fernández⁸, Ricardo Blanco¹, Oreste Gualillo⁹, Javier Martin¹⁰, Javier Llorca¹¹, Raquel Lopez-Mejías¹ and Miguel Angel González-Gay^1,12, ¹Epidemiology, Genetics and Atherosclerosis Research Group on Systemic Inflammatory Diseases, IDIVAL, Santander, Spain, Santander, Spain, ²Rheumatology Division, Hospital Comarcal de Laredo, Laredo, Spain, ³Rheumatology Division, Hospital Universitario de Canarias, Santa Cruz de Tenerife, Spain, ⁴Rheumatology Division, Hospital Universitario de Canarias, La Laguna, Spain, ⁵Rheumatology Division, Hospital Universitario de La Princesa, IIS-Princesa, Madrid, Spain, ⁶Rheumatology Division, Hospital General Universitario de Elda, Elda, Spain, ⁷Rheumatology Division, Hospital General Universitario de Alicante, Alicante, Spain, ⁸Rheumatology Division, Hospital General Universitario de Ciudad Real, Ciudad Real, Spain, ⁹SERGAS (Servizo Galego de Saude) and IDIS (Instituto de Investigación Sanitaria de Santiago), The NEIRID Group (Neuroendocrine Interactions in Rheumatology and Inflammatory Diseases), Santiago University Clinical Hospital, Santiago de Compostela, Spain, Santiago de Compostela, Spain, ¹⁰Instituto de Parasitología y Biomedicina ‘López-Neyra’, CSIC, PTS Granada, Granada, Spain., Granada, Spain, ¹¹Department of Epidemiology and Computational Biology, School of Medicine, University of Cantabria, and CIBER Epidemiología y Salud Pública (CIBERESP), IDIVAL, Santander, Spain, ¹²School of Medicine, University of Cantabria, Santander, Spain, Santander, Spain
Background/Purpose: Cardiovascular (CV) disease (mainly due to accelerated atherosclerosis) is one of the main causes of mortality in axial spondyloarthritis (axSpA). The higher incidence of…
Abstract Number: 691 • 2018 ACR/ARHP Annual Meeting
A Service Evaluation of Reporting Standards of Computer Tomography Defined Sacroiliitis Suggestive of Axial Spondyloarthritis in Inflammatory Bowel Disease Patients Imaged for Non-Musculoskeletal Indications
Chong Seng Edwin Lim¹, Samantha Bee Lian Low², Baljeet Dhillon², Shin Azegami², Andoni Paul Toms² and Karl Gaffney¹, ¹Rheumatology, Norfolk and Norwich University Hospital, Norwich, United Kingdom, ²Radiology, Norfolk and Norwich University Hospital, Norwich, United Kingdom
Background/Purpose: A combined service evaluation by the rheumatology and radiology department was undertaken to understand the frequency and reporting standards of Computer Tomography-defined Sacroiliitis (CTSI)…
Abstract Number: 2076 • 2018 ACR/ARHP Annual Meeting
Transmembrane TNF (tmTNF) Transgenic Mice Exhibit Enlarged Lymph Nodes and Elevated Numbers of High Endothelial Cells Associated with Increased Lymphocyte Recruitment
Kim Jeucken¹, Jan Piet van Hamburg², Merlijn Kaaij³, Leonie van Duivenvoorde³, Dominique Baeten³ and Sander W. Tas², ¹2Department of Clinical Immunology & Rheumatology and Laboratory for Experimental Immunology, Academic Medical Center, University of Amsterdam, Amsterdam, Netherlands, ²Amsterdam Rheumatology & immunology Center | Department of Experimental Immunology, Academic Medical Center, University of Amsterdam, Amsterdam, Netherlands, ³Department of Clinical Immunology & Rheumatology and Department of Experimental Immunology, Academic Medical Center, University of Amsterdam, Amsterdam, Netherlands
Background/Purpose: The NF-κB family of transcription factors plays a crucial role in chronic inflammatory diseases and can be activated via two distinct pathways. Non-canonical NF-κB…
Abstract Number: 692 • 2018 ACR/ARHP Annual Meeting
TNF Inhibitor Dose Tapering in Axial Spondyloarthritis: A Systematic Review and Meta-Analysis
Daeria O. Lawson^1,2, Maria Eraso³, Lawrence Mbuagbaw⁴, Theresa Aves⁵, Alvin Leenus⁴, Marianinha Joanes⁶, Ahmed Omar^1,7 and Robert D Inman^8,9, ¹Rheumatology, Toronto Western Hospital, Toronto, ON, Canada, Toronto, ON, Canada, ²Department of Health Research Methods, Evidence and Impact, McMaster University, Hamilton, ON, Canada, Hamilton, ON, Canada, ³Toronto Western Hospital, Toronto, ON, Canada, Tornoto, ON, Canada, ⁴McMaster University, Hamilton, ON, Canada, Hamilton, ON, Canada, ⁵St. Michael's Hospital, Toronto, ON, Canada, Toronto, ON, Canada, ⁶Boston University School of Medicine, Boston, MA, United States, Boston, MA, ⁷Rheumatology, University of Toronto, Toronto, ON, Canada, Toronto, ON, Canada, ⁸Toronto Western Hospital, Toronto, ON, Canada, Toronto, ON, Canada, ⁹University of Toronto, Toronto, ON, Canada, Toronto, ON, Canada
Background/Purpose: Patients with axial spondyloarthritis (axSpA) who have achieved a stable disease state and are undergoing treatment with tumour necrosis factor inhibitor (TNFi) therapy may…
Abstract Number: 2133 • 2018 ACR/ARHP Annual Meeting
Comparative Disease Burden of Patients with Rheumatoid Arthritis, Psoriatic Arthritis, and Axial Spondyloarthritis: Data from the Corrona Rheumatoid Arthritis and Psoriatic Arthritis/Spondyloarthritis (PsA/SpA) Registries
Philip J. Mease¹, Mei Liu², Sabrina Rebello³, Hyungjoo Kang², Yujin Park⁴ and Jeffrey Greenberg^2,5, ¹Swedish Medical Center and University of Washington, Seattle, WA, ²Corrona, LLC, Waltham, MA, ³Corrona, LLC, Southborough, MA, ⁴Novartis Pharmaceuticals Corporation, East Hanover, NJ, ⁵New York University School of Medicine, New York, NY
Background/Purpose: Rheumatoid arthritis (RA), psoriatic arthritis (PsA), and axial spondyloarthritis (axSpA) are 3 common inflammatory rheumatic diseases that can lead to deformities and joint destruction;…
Abstract Number: 893 • 2018 ACR/ARHP Annual Meeting
Identification of Axial Spondyloarthritis Patients in a Large Dataset: The Development and Validation of Novel Methods
Rebecca S. Overbury¹, Shaobo Pei², Gopi Penmetsa², Grant W. Cannon², Daniel O. Clegg³, Brian Sauer⁴ and Jessica Walsh⁵, ¹Internal Medicine, Divison of Rheumatology, University of Utah Medical Center, Salt Lake City, UT, ²University of Utah, Salt Lake City, UT, ³Division of Rheumatology, University of Utah Medical Center, Salt Lake City, UT, ⁴Salt Lake City VA Medical Center and University of Utah, Salt Lake City, UT, ⁵Rheumatology, Salt Lake City Veterans Affairs, Salt Lake City, UT
Background/Purpose: Big data research in axial spondyloarthritis (axSpA) is limited by a lack of adequate methods for identifying axSpA patients, since there are no billing…
Abstract Number: 2537 • 2018 ACR/ARHP Annual Meeting
Benefit Study: Results of Interim Analysis of a Pan-European Observational Study to Evaluate Real-World Effectiveness of SB4 Following Transition from Originator Etanercept (ETN) in Patients with Rheumatoid Arthritis (RA) or Axial Spondyloarthritis (AxSpA)
Klaus Krüger¹, Carlo Selmi^2,3, Alain Cantagrel⁴, Miguel A. Abad⁵, Ulrich Freudensprung⁶, Mourad Farouk Rezk⁶ and Janet Addison⁷, ¹Medical Centre of Rheumatology, Munich, Germany, ²Rheumatology and Clinical Immunology Unit, Humanitas Research Hospital, Rozzano (MI), Italy, ³BIOMETRA Department, University of Milan, Milan, Italy, ⁴Center of Rheumatology of CHU, Toulouse, France, ⁵FEA Reumatología, Hospital Virgen del Puerto, Cáceres, Spain, ⁶Biogen International GmbH, Zug, Switzerland, ⁷Biogen Idec, Maidenhead, United Kingdom
Background/Purpose: SB4, a biosimilar to the reference ETN, received EU marketing authorisation in January 2016, based on the totality of evidence from pre-clinical and clinical…
Abstract Number: 1024 • 2018 ACR/ARHP Annual Meeting
Unique Pattern of Lectin Pathway Complement Protein Levels in Axial Spondyloarthritis
Anne Troldborg^1,2,3, Steffen Thiel¹, Clara Mistegaard Joergensen⁴, Kristian Stengaard-Pedersen^3,5 and Anne Gitte Loft^3,6, ¹Biomedicine, Aarhus University, Aarhus, Denmark, ²clinical medicine, Aarhus University, Aarhus, Denmark, ³Rheumatology, Aarhus University Hospital, Aarhus, Denmark, ⁴Emergency Medicine, Regional Hospital Horsens, Horsens, Denmark, ⁵Clinical medicine, Aarhus University, Aarhus, Denmark, ⁶Clinical Medicine, Aarhus University, Aarhus, Denmark
Background/Purpose: Spondyloarthritis (SpA) represents a group of immune-mediated inflammatory diseases that exhibit overlapping clinical features, genetic predisposition and a not fully understood pathogenesis. Inflammation and…
Abstract Number: 2558 • 2018 ACR/ARHP Annual Meeting
Efficacy and Safety Outcomes in Patients with Axial Spondyloarthritis Treated with Certolizumab Pegol: Results from the 48-Week Run-in Part of a Withdrawal Study (NCT02505542)
Robert B.M. Landewé¹, Désirée van der Heijde², Maxime Dougados³, Xenofon Baraliakos⁴, Filip van Den Bosch⁵, Bengt Hoepken⁶, Karen Thomas⁶ and Lianne S. Gensler⁷, ¹Amsterdam Rheumatology & Clinical Immunology Center, Amsterdam and Zuyderland MC, Heerlen, Netherlands, ²Leiden University Medical Centre, Leiden, Netherlands, ³Rheumatology B Department, Paris-Descartes University and Cochin Hospital, Paris, France, ⁴Ruhr-University Bochum, Herne, Germany, ⁵Department of Internal Medicine, Ghent University Hospital, Ghent, Belgium, ⁶UCB Pharma, Monheim, Germany, ⁷University of California, San Francisco, CA
Background/Purpose: C-OPTIMISE is the first trial to evaluate whether certolizumab pegol (CZP) can be reduced/discontinued in patients with radiographic(r)-axSpA/ankylosing spondylitis (AS) and non-radiographic(nr)-axSpA achieving sustained…

« Previous Page
1
…
6
7
8
9
10
…
16
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].